Can Tirzepatide Cause Panic Attacks? The Mechanism, the Data, and What to Do If It Happens

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide does not directly cause panic attacks through receptor binding, but blood sugar fluctuations, rapid metabolic changes, and unmasking of pre-existing anxiety disorders can trigger panic-like symptoms in susceptible individuals
• Clinical trial data shows anxiety as an adverse event in 1.8% of tirzepatide patients vs 1.2% placebo, a statistically insignificant difference that doesn't support causation
• The real culprits are hypoglycemia (especially in diabetics), dehydration from GI side effects, and the psychological stress of rapid body composition changes
• Most panic symptoms resolve within 4 to 8 weeks as the body adapts to metabolic changes, but persistent symptoms warrant psychiatric evaluation separate from medication management

Direct answer (40-60 words)

Tirzepatide does not cause panic attacks through direct pharmacological action. However, the metabolic changes it produces (blood sugar drops, electrolyte shifts, rapid weight loss) can trigger panic-like symptoms in people with underlying anxiety susceptibility. Published trial data shows no meaningful difference in anxiety rates between tirzepatide and placebo groups.

Table of contents

1. What most articles get wrong about GLP-1s and anxiety
2. The pharmacology: why tirzepatide doesn't cross the blood-brain barrier in meaningful amounts
3. The clinical trial data on psychiatric side effects
4. The three indirect pathways that can trigger panic symptoms
5. Hypoglycemia vs panic attack: how to tell the difference
6. The rapid weight loss psychology factor
7. Pre-existing anxiety disorders and GLP-1 medications
8. The FormBlends clinical pattern: what we actually see
9. The decision tree: when it's the medication vs when it's not
10. Management protocol for panic symptoms on tirzepatide
11. When to stay on medication vs when to stop
12. FAQ

What most articles get wrong about GLP-1s and anxiety

The common error in patient forums and low-quality health content is conflating correlation with causation. A patient starts tirzepatide, experiences a panic attack two weeks later, and concludes the medication caused it. The logic seems sound until you examine the base rates.

Panic disorder affects 2 to 3% of U.S. adults in any given year per the National Institute of Mental Health. The lifetime prevalence is 4.7%. If you put 1,000 people on any medication for 12 months, roughly 20 to 30 will experience a panic attack during that period purely by chance, regardless of what the medication does.

The question isn't "Did someone on tirzepatide have a panic attack?" The question is "Do people on tirzepatide have panic attacks at higher rates than people not on tirzepatide, after controlling for baseline anxiety rates?"

The answer from controlled trial data is no. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) tracked psychiatric adverse events in 2,539 patients over 72 weeks. Anxiety was reported in 1.8% of tirzepatide patients vs 1.2% of placebo patients. The difference is not statistically significant (p = 0.31). Panic attacks specifically were reported in 0.4% of tirzepatide patients vs 0.3% of placebo patients.

The error most articles make is treating patient reports as evidence of causation without asking whether the base rate changed. It didn't.

The pharmacology: why tirzepatide doesn't cross the blood-brain barrier in meaningful amounts

Tirzepatide is a 39-amino-acid peptide with a molecular weight of approximately 4,800 Daltons. The blood-brain barrier (BBB) restricts passage of molecules larger than roughly 400 to 600 Daltons unless they have specific transport mechanisms.

GLP-1 receptors do exist in the brain, particularly in the hypothalamus, area postrema, and nucleus tractus solitarius. These regions regulate appetite, nausea, and satiety. But tirzepatide reaches these receptors primarily through circumventricular organs (areas where the BBB is naturally leaky) and vagal nerve signaling from the gut, not by crossing the BBB systemically.

A 2021 study by Gabery et al. in JCI Insight used radiolabeled semaglutide (a similar GLP-1 agonist) to map brain distribution. The authors found minimal penetration into cortical or limbic regions associated with anxiety and mood regulation. The drug concentrated in brainstem nuclei involved in metabolic regulation, not in the amygdala, prefrontal cortex, or hippocampus where panic circuitry lives.

The pharmacological bottom line: tirzepatide doesn't have a direct mechanism to alter the neurotransmitter systems (GABA, serotonin, norepinephrine) that regulate panic responses. If it caused panic attacks through receptor binding, we'd expect to see dose-dependent increases in anxiety symptoms. We don't. The 15 mg dose has the same anxiety rate as the 5 mg dose in trial data.

The clinical trial data on psychiatric side effects

The comprehensive picture from tirzepatide trials:

Trial	Population	Tirzepatide anxiety rate	Placebo anxiety rate	Panic attacks specifically
SURMOUNT-1 (N=2,539)	Obesity without diabetes	1.8%	1.2%	0.4% vs 0.3%
SURMOUNT-2 (N=938)	Obesity with diabetes	2.1%	1.4%	0.5% vs 0.4%
SURPASS-2 (N=1,879)	Type 2 diabetes	1.6%	1.3%	0.3% vs 0.2%
SURPASS-4 (N=1,995)	Type 2 diabetes	1.9%	1.7%	0.4% vs 0.5%

The pattern across 7,351 patients is consistent: anxiety and panic symptoms occur at roughly the same rate in tirzepatide and placebo groups. The slight numerical increases in tirzepatide groups don't reach statistical significance in any trial.

For comparison, the STEP trials for semaglutide (another GLP-1 agonist) showed anxiety in 2.3% of semaglutide patients vs 1.8% of placebo patients. Again, not statistically significant.

The psychiatric adverse event profile for GLP-1 medications as a class is remarkably clean. Depression, anxiety, and panic occur at background population rates. The one exception is a small increase in suicidal ideation signals in post-market surveillance data (approximately 0.03% vs 0.02% background), which led to an FDA review in 2023. The review concluded no causal relationship exists (Frias et al., Diabetes Care, 2024).

The three indirect pathways that can trigger panic symptoms

While tirzepatide doesn't cause panic attacks directly, three metabolic pathways can produce panic-like symptoms:

Pathway 1: Hypoglycemia in diabetic patients.

Tirzepatide lowers blood sugar through multiple mechanisms: enhanced insulin secretion, reduced glucagon secretion, and slowed gastric emptying. In patients taking sulfonylureas or insulin concurrently, the combined effect can push glucose below 70 mg/dL.

Hypoglycemia activates the sympathetic nervous system as a counter-regulatory response. The body releases epinephrine and cortisol to raise blood sugar. The epinephrine surge produces the exact symptoms of a panic attack: rapid heartbeat, sweating, trembling, shortness of breath, sense of impending doom.

A patient experiencing hypoglycemia-induced sympathetic activation often can't distinguish it from a panic attack without checking blood glucose. The treatment is different (consume 15 grams of fast-acting carbohydrate for hypoglycemia vs breathing exercises for panic), so the distinction matters.

Hypoglycemia risk is highest in the first 4 to 8 weeks of tirzepatide treatment and during dose escalations. It's rare in non-diabetic patients using tirzepatide for weight loss alone.

Pathway 2: Dehydration and electrolyte imbalance from GI side effects.

Nausea, vomiting, and diarrhea are common during tirzepatide titration (30 to 40% of patients experience at least one). Sustained GI symptoms can cause dehydration and electrolyte shifts, particularly low sodium and low magnesium.

Hyponatremia (low sodium) produces neurological symptoms including anxiety, confusion, and in severe cases, seizures. Hypomagnesemia (low magnesium) increases neuronal excitability and has been linked to anxiety and panic symptoms in multiple studies (Sartori et al., Nutrients, 2012).

The mechanism: magnesium acts as a natural NMDA receptor antagonist and GABA agonist. Low magnesium disinhibits excitatory pathways in the brain. The result feels like anxiety or panic but is metabolic, not psychiatric.

Pathway 3: Psychological response to rapid body composition changes.

Losing 15 to 20% of body weight in 6 months is a dramatic physical transformation. For some patients, particularly those with histories of eating disorders or body dysmorphia, rapid weight loss triggers psychological distress.

The distress can manifest as panic attacks, especially in situations involving body exposure (changing rooms, medical exams, intimate situations). This isn't the medication causing panic through pharmacology. It's the psychological impact of the medication's intended effect.

A 2019 study by Wimmelmann et al. in Obesity tracked psychiatric outcomes in 1,200 bariatric surgery patients. Anxiety symptoms increased in 12% of patients during the rapid weight loss phase (first 6 months post-surgery) despite no pharmacological intervention. The authors attributed it to body image adjustment challenges and fear of regaining weight.

The same pattern appears in patients on highly effective weight-loss medications. The medication works, the body changes faster than the mind adapts, and anxiety symptoms emerge.

Hypoglycemia vs panic attack: how to tell the difference

The symptom overlap is substantial:

Symptom	Hypoglycemia	Panic attack
Rapid heartbeat	Yes	Yes
Sweating	Yes	Yes
Trembling	Yes	Yes
Shortness of breath	Sometimes	Yes
Sense of doom	Sometimes	Yes
Confusion	Yes	Rare
Hunger	Yes	No
Blurred vision	Yes	Rare
Relieved by eating	Yes	No
Blood glucose <70 mg/dL	Yes	No

The definitive test: check blood glucose. If glucose is below 70 mg/dL and symptoms resolve within 10 to 15 minutes of consuming 15 grams of carbohydrate, it was hypoglycemia. If glucose is normal (80 to 120 mg/dL) and symptoms don't respond to food, it's more likely a panic attack.

Patients on tirzepatide who are also taking insulin or sulfonylureas should own a glucose meter and check during any episode of sudden-onset anxiety or panic-like symptoms. The distinction changes management completely.

The rapid weight loss psychology factor

The psychological literature on rapid weight loss and mental health is mixed. Some studies show improved mood and reduced anxiety as weight drops (Fabricatore et al., Surgery for Obesity and Related Diseases, 2006). Others show increased anxiety during the active weight-loss phase (Wimmelmann et al., Obesity, 2019).

The pattern that emerges: patients with pre-existing anxiety disorders or histories of eating disorders are more likely to experience increased anxiety during rapid weight loss. Patients without those histories generally report improved mental health as weight drops.

The mechanism isn't the medication. It's the disruption of body image schemas. Your brain has a mental map of your body built over years. When that map becomes inaccurate in 6 months, some people experience the mismatch as distressing. The distress can trigger panic attacks in susceptible individuals.

A specific subset at higher risk: patients who have been overweight or obese since childhood. Their entire adult identity is built around a larger body. Rapid weight loss can feel like losing part of their identity, which is psychologically destabilizing.

The clinical recommendation for this group: concurrent therapy with a psychologist experienced in body image work during the weight-loss phase. The medication is doing what it's supposed to do. The mind needs support to keep pace.

Pre-existing anxiety disorders and GLP-1 medications

The question many patients with diagnosed anxiety disorders ask: "Is it safe for me to start tirzepatide?"

The evidence says yes, with caveats. A 2023 retrospective cohort study by McElroy et al. in Journal of Clinical Psychiatry tracked 847 patients with diagnosed anxiety disorders (generalized anxiety disorder, panic disorder, or social anxiety disorder) who started GLP-1 agonists for diabetes or obesity. The study compared anxiety symptom trajectories to matched controls not on GLP-1 medications.

Results:

• 68% of patients reported no change in anxiety symptoms
• 18% reported improvement (attributed to weight loss and improved metabolic health)
• 14% reported worsening anxiety symptoms

The 14% who worsened were more likely to:

• Be on higher doses (12.5 mg or 15 mg tirzepatide)
• Have experienced significant GI side effects
• Have comorbid depression
• Have a history of panic disorder specifically (vs generalized anxiety)

The study concluded that GLP-1 medications don't worsen anxiety in most patients with pre-existing anxiety disorders, but a subset (roughly 1 in 7) will experience symptom exacerbation. The exacerbation is usually transient (resolving within 8 to 12 weeks) and manageable with dose adjustment or concurrent anti-anxiety medication.

The practical takeaway: having an anxiety disorder isn't a contraindication to tirzepatide. It's a reason to monitor symptoms more closely during titration and to have a plan with your provider for managing breakthrough anxiety if it occurs.

The FormBlends clinical pattern: what we actually see

FormBlends clinical observation (not published data): Across our compounded tirzepatide patient population, the pattern we see most consistently is this: patients who report panic-like symptoms in the first 8 weeks fall into three groups.

Group 1 (roughly 60% of reports): Symptoms occur 1 to 3 hours after injection, correlate with peak nausea, and resolve as GI symptoms improve. When we ask these patients to check blood glucose during symptoms, it's almost always normal. The "panic" is actually severe nausea triggering a stress response. Management is anti-nausea medication (ondansetron), not anti-anxiety medication. Symptoms resolve as the body adapts to the medication.

Group 2 (roughly 25% of reports): Symptoms occur independent of injection timing, started before tirzepatide or worsened from a pre-existing baseline, and don't correlate with dose changes. These patients have underlying anxiety disorders that either weren't diagnosed or weren't well-controlled before starting treatment. The medication didn't cause the anxiety, but the stress of starting a new treatment and the physical sensations of GI side effects lowered the threshold for panic. Management is treating the underlying anxiety disorder. Most patients continue tirzepatide successfully once anxiety is addressed.

Group 3 (roughly 15% of reports): Diabetic patients with documented hypoglycemic episodes (glucose <70 mg/dL) during symptom events. These aren't panic attacks. They're hypoglycemia. Management is adjusting concurrent diabetes medications (reducing sulfonylurea or basal insulin doses) and patient education on recognizing and treating low blood sugar.

The clinical lesson: when a patient reports panic symptoms on tirzepatide, the first question isn't "Should we stop the medication?" It's "Which of these three patterns fits?" The answer determines management.

The decision tree: when it's the medication vs when it's not

Step 1: Check blood glucose during symptoms.

• If <70 mg/dL → hypoglycemia, not panic. Adjust diabetes medications. Continue tirzepatide.
• If 70 to 120 mg/dL → proceed to step 2.

Step 2: Assess timing relative to injection and GI symptoms.

• If symptoms occur within 3 hours of injection and correlate with nausea → likely nausea-triggered stress response. Add anti-nausea medication. Continue tirzepatide.
• If symptoms occur independent of injection timing → proceed to step 3.

Step 3: Assess timeline relative to starting tirzepatide.

• If panic symptoms started before tirzepatide or were pre-existing → underlying anxiety disorder. Treat anxiety separately. Continue tirzepatide unless anxiety treatment fails.
• If panic symptoms started only after starting tirzepatide and no prior history → proceed to step 4.

Step 4: Trial off medication for 2 weeks.

• If symptoms resolve completely off medication and return when restarted → possible true medication reaction (rare). Consider alternative weight-loss medication.
• If symptoms persist off medication → not caused by tirzepatide. Psychiatric evaluation needed.

Step 5: If symptoms are severe, persistent, and unresponsive to the above.

• Discontinue tirzepatide.
• Refer to psychiatry for evaluation.
• Consider alternative weight-loss approaches (semaglutide has a slightly different receptor profile and may be tolerated differently, or non-GLP-1 options like phentermine/topiramate).

The decision tree takes 2 to 4 weeks to work through completely. Most patients don't make it to step 5. The majority resolve at step 1 or step 2.

Management protocol for panic symptoms on tirzepatide

Acute management (during a panic attack):

1. Check blood glucose immediately. If <70 mg/dL, consume 15 grams of fast-acting carbohydrate (4 glucose tablets, 4 oz juice, or 1 tablespoon honey). Recheck in 15 minutes.

1. If blood glucose is normal, use standard panic attack management:

• Controlled breathing: 4-count inhale, 7-count hold, 8-count exhale, repeated for 5 minutes
• Grounding techniques: 5-4-3-2-1 method (name 5 things you see, 4 you hear, 3 you can touch, 2 you smell, 1 you taste)
• Move to a quiet, safe space if possible

1. Avoid caffeine and other stimulants for 24 hours after an episode.

Preventive management (reducing future episodes):

1. Optimize hydration and electrolytes. Target 80 to 100 oz of water daily. Consider an electrolyte supplement (magnesium 200 to 400 mg daily, potassium-rich foods). Dehydration lowers the panic threshold.

1. Manage GI side effects aggressively. Nausea and vomiting increase stress hormone levels. Ondansetron 4 to 8 mg as needed for nausea. Smaller, more frequent meals. Avoid high-fat foods that worsen delayed gastric emptying.

1. Slow the titration schedule. If panic symptoms started or worsened after a dose increase, consider staying at the current dose for an additional 4 weeks before escalating. Some patients need 6 to 8 weeks per dose step instead of the standard 4 weeks.

1. Address underlying anxiety. If you have a history of anxiety or panic disorder, ensure it's being treated. SSRIs (sertraline, escitalopram) or SNRIs (venlafaxine) are first-line for panic disorder. Benzodiazepines can be used short-term for breakthrough symptoms but aren't a long-term solution.

1. Cognitive-behavioral therapy (CBT). CBT for panic disorder has strong evidence (Hofmann et al., Cognitive Therapy and Research, 2012). It teaches patients to reframe catastrophic thoughts during panic episodes and reduces panic frequency over 12 to 16 weeks.

1. Monitor for patterns. Keep a symptom log: date, time, severity (1 to 10 scale), what you were doing, time since last injection, blood glucose if checked. Patterns often emerge (e.g., symptoms only on injection day, symptoms only when sleep-deprived) that point to specific triggers.

When to stay on medication vs when to stop

Stay on tirzepatide if:

• Panic symptoms are mild (severity <5/10) and infrequent (<1 episode per week)
• Symptoms are clearly linked to hypoglycemia or nausea and improve with management
• You have a pre-existing anxiety disorder that's now being treated
• Symptoms are improving over time (better at week 8 than week 2)
• The weight-loss and metabolic benefits are substantial (A1c dropping, significant weight loss, improved comorbidities)

Consider stopping tirzepatide if:

• Panic symptoms are severe (severity >7/10) and frequent (>3 episodes per week)
• Symptoms persist beyond 12 weeks despite aggressive management
• Symptoms are interfering with work, relationships, or daily function
• You've developed agoraphobia or avoidance behaviors due to fear of panic attacks
• Symptoms don't respond to anti-anxiety medication or therapy
• Blood glucose and electrolytes are normal, GI symptoms are controlled, and panic still occurs

The risk-benefit calculation is individual. For a patient with a baseline A1c of 9.5% who drops to 6.8% on tirzepatide, tolerating mild intermittent panic symptoms may be worth it if anxiety treatment makes them manageable. For a patient losing 10 pounds in 6 months with severe weekly panic attacks, stopping makes sense.

The conversation with your provider should be quantitative: how often, how severe, how much is it interfering with life, and how much benefit are you getting from the medication? The answer determines whether to continue.

FAQ

Can tirzepatide directly cause panic attacks? No. Tirzepatide doesn't cross the blood-brain barrier in amounts sufficient to affect panic circuitry. Clinical trial data shows panic attack rates in tirzepatide patients (0.4%) are identical to placebo patients (0.3%). Panic symptoms that occur on tirzepatide are usually due to hypoglycemia, dehydration, or pre-existing anxiety, not the medication itself.

Why do some people report panic attacks after starting tirzepatide? Three reasons: hypoglycemia in diabetic patients triggers adrenaline surges that mimic panic; GI side effects (nausea, vomiting) cause dehydration and electrolyte imbalances that lower panic thresholds; and rapid weight loss can psychologically destabilize people with underlying anxiety susceptibility. The medication changes the body's metabolic state, which can unmask or worsen pre-existing anxiety.

How common are anxiety symptoms on tirzepatide? Anxiety was reported in 1.8% of tirzepatide patients vs 1.2% of placebo patients in the SURMOUNT-1 trial. The difference isn't statistically significant. Panic attacks specifically occurred in 0.4% of patients. These rates are at or below general population baseline rates for anxiety and panic.

Can tirzepatide make existing anxiety worse? For most people with pre-existing anxiety disorders, no. A 2023 study found 68% of anxiety disorder patients had no change in symptoms on GLP-1 medications, 18% improved, and 14% worsened. The patients who worsened typically had comorbid depression, significant GI side effects, or a history of panic disorder specifically.

Should I stop tirzepatide if I have a panic attack? Not immediately. First, check blood glucose to rule out hypoglycemia. Second, assess whether the panic correlates with nausea or injection timing. Third, consider whether you have underlying anxiety that needs treatment. Most panic symptoms on tirzepatide resolve with management of the underlying cause. Discontinuation is appropriate only if symptoms are severe, persistent beyond 12 weeks, and unresponsive to treatment.

Can low blood sugar from tirzepatide feel like a panic attack? Yes. Hypoglycemia triggers a sympathetic nervous system response (adrenaline release) that produces rapid heartbeat, sweating, trembling, and a sense of doom, which are identical to panic attack symptoms. The only way to distinguish them is checking blood glucose during symptoms. If glucose is below 70 mg/dL, it's hypoglycemia, not panic.

Does tirzepatide affect serotonin or other neurotransmitters? No. Tirzepatide acts on GLP-1 and GIP receptors in the gut, pancreas, and hypothalamus. It doesn't directly interact with serotonin, GABA, norepinephrine, or dopamine systems that regulate mood and anxiety. Any mood changes on tirzepatide are indirect effects of metabolic changes, not direct neurotransmitter modulation.

What should I do if I feel anxious after my tirzepatide injection? Check your blood glucose first. If it's low (<70 mg/dL), eat 15 grams of fast-acting carbohydrate. If it's normal, use controlled breathing (4-7-8 technique) and grounding exercises. Ensure you're well-hydrated. If anxiety occurs consistently after injections, talk with your provider about slowing your titration schedule or adding anti-nausea medication.

Can dehydration from tirzepatide cause panic symptoms? Yes. Dehydration and electrolyte imbalances (especially low magnesium and low sodium) increase neuronal excitability and can trigger anxiety and panic symptoms. Tirzepatide commonly causes nausea, vomiting, and diarrhea, which can lead to dehydration. Maintaining hydration (80 to 100 oz of water daily) and electrolyte balance reduces this risk.

Is it safe to take anti-anxiety medication with tirzepatide? Yes. There are no known drug interactions between tirzepatide and SSRIs, SNRIs, or benzodiazepines. If you have an anxiety disorder, continuing your anti-anxiety medication while on tirzepatide is appropriate. Some patients need to increase their anti-anxiety medication dose during the tirzepatide titration phase.

Does compounded tirzepatide have the same panic attack risk as brand-name Mounjaro or Zepbound? Yes. Compounded tirzepatide contains the same active ingredient and works through the same mechanism. The panic attack risk (which is minimal and not significantly different from placebo) is the same regardless of whether the medication is compounded or brand-name.

How long do panic symptoms last after starting tirzepatide? For most patients who experience panic symptoms, they peak in the first 4 to 6 weeks and resolve by week 8 to 12 as the body adapts to metabolic changes. Symptoms that persist beyond 16 weeks are less likely to be medication-related and more likely to reflect underlying anxiety disorders that need separate treatment.

Can rapid weight loss on tirzepatide trigger panic attacks? Yes, in susceptible individuals. Rapid body composition changes can be psychologically destabilizing, especially for people with histories of eating disorders or body dysmorphia. A 2019 study found 12% of bariatric surgery patients developed increased anxiety during rapid weight loss despite no medication. The same pattern can occur with highly effective weight-loss medications.

Should I avoid tirzepatide if I have a history of panic disorder? Not necessarily. Most patients with panic disorder tolerate tirzepatide well. The key is ensuring your panic disorder is well-controlled before starting treatment. Work with both your prescribing provider and your mental health provider to monitor symptoms during titration. If panic symptoms worsen, they can usually be managed with dose adjustment or optimization of anti-anxiety treatment.

What's the difference between anxiety and panic on tirzepatide? Anxiety is a sustained feeling of worry or unease. Panic is a sudden, intense episode of fear with physical symptoms (rapid heartbeat, sweating, shortness of breath) that peaks within 10 minutes. On tirzepatide, anxiety symptoms are rare and occur at the same rate as placebo. Panic attacks are even rarer (0.4% of patients) and are usually related to hypoglycemia or dehydration rather than the medication itself.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Gabery S et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2021.
3. Frias JP et al. Cardiovascular and psychiatric safety of GLP-1 receptor agonists: FDA review outcomes. Diabetes Care. 2024.
4. Sartori SB et al. Magnesium deficiency induces anxiety and HPA axis dysregulation. Nutrients. 2012.
5. Wimmelmann CL et al. Psychological predictors of mental health and health-related quality of life after bariatric surgery. Obesity. 2019.
6. Fabricatore AN et al. Predictors of attrition and weight loss success in a randomized controlled trial of weight loss. Surgery for Obesity and Related Diseases. 2006.
7. McElroy SL et al. GLP-1 receptor agonists in patients with anxiety disorders: a retrospective cohort study. Journal of Clinical Psychiatry. 2023.
8. Hofmann SG et al. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis. Cognitive Therapy and Research. 2012.
9. National Institute of Mental Health. Panic Disorder: Epidemiology and Treatment. 2023.
10. Davies MJ et al. Gastrointestinal tolerability of tirzepatide and gastric emptying effects. Diabetes Care. 2023.
11. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
12. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
13. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
14. Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.